Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 7/20 | 0.59 |
| ▸ | ADRA2A | P08913 | 5/20 | 0.59 |
| ▸ | CRYZ | Q08257 | 1/20 | 0.43 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.41 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | TDP2 | O95551 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3353230 | 0.88 | PNMT (0.59) | PNMTADRA2AADRA2BADRA2CMEN1 | |
| Hydrochloric Acid SCHEMBL7484155 | 0.87 | PNMT (0.57) | PNMTADRA2AADRA2BADRA2CMEN1 | |
| Hydrochloric Acid SCHEMBL8102356 | 0.80 | MAPT (0.50) | PNMTADRA2AADRA2BADRA2CMEN1 | |
| SCHEMBL2247008 | 0.79 | PNMT (0.46) | PNMTADRA2ACRYZADRA2BADRA2C | |
| SCHEMBL30094887 | 0.78 | MAPT (0.46) | PNMTADRA2AMEN1MAPTKMT2A | |
| SCHEMBL4950162 | 0.77 | FABP6 (0.49) | PNMTADRA2AMEN1MAPTKMT2A | |
| SCHEMBL27339670 | 0.76 | ADRA2A (0.44) | PNMTADRA2ACRYZMEN1MAPT | |
| SCHEMBL303351 | 0.75 | MEN1 (0.46) | PNMTADRA2AMEN1MAPTKMT2A | |
| SCHEMBL31021147 | 0.75 | MEN1 (0.46) | PNMTADRA2AMEN1MAPTKMT2A | |
| SCHEMBL28566911 | 0.75 | MAPT (0.46) | PNMTADRA2ACRYZADRA2BADRA2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116332910-A | 2-aminopyrimidine derivatives as kinase inhibitors, preparation and use thereof | 江苏威凯尔医药科技有限公司 | 2023-06-27 | — | — | CN | disclosed |
| EP-3564232-B1 | BMP-SIGNAL-INHIBITING COMPOUND | RIKEN (JP) | 2022-01-26 | — | — | EP | disclosed |
| US-10954216-B2 | BMP-signal-inhibiting compound | RIKEN (JP) | 2021-03-23 | — | — | US | disclosed |
| US-20190337926-A1 | BMP-SIGNAL-INHIBITING COMPOUND | RIKEN (JP) | 2019-11-07 | — | — | US | disclosed |
| EP-3564232-A1 | BMP-SIGNAL-INHIBITING COMPOUND | Riken (JP) | 2019-11-06 | — | — | EP | disclosed |
| WO-2008144483-A2 | AGENTS FOR TREATING DISORDERS INVOLVING MODULATION OF RYANODINE RECEPTORS | ARMGO PHARMA, INC. (US) | 2008-11-27 | — | — | WO | disclosed |
| WO-2008144483-A2 | AGENTS FOR TREATING DISORDERS INVOLVING MODULATION OF RYANODINE RECEPTORS | ARMGO PHARMA, INC. (US) | 2008-11-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10954216-B2 | BMP-signal-inhibiting compound | BMP1, BMP2, BMP4 | PNMT 4701/4885ADRA2A 3676/4885CRYZ 3566/4885 |
| US-20190337926-A1 | BMP-SIGNAL-INHIBITING COMPOUND | BMP1, BMP2, BMPR2 | PNMT 4608/4885ADRA2A 3413/4885CRYZ 1376/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.